via Johns Hopkins University
Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn’s disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.
But the costly, time-consuming manufacturing process to produce antibodies prevents these treatments from being accessible to most patients.
Andrew Zydney, Bayard D. Kunkle Chair and professor of chemical engineering at Penn State, has identified a new method to manufacture antibodies, which could drive down the production cost. His research results were recently published in Biotechnology Progress.
“If you look at the top 10 best-selling medications, by annual sales, eight are in the category of monoclonal antibodies,” Zydney said. “And every year, individuals and insurance companies spend upwards of $100 billion on antibodies, with costs to treat a single patient often exceeding $50,000. There remains a huge unmet need for these products in treating a growing range of diseases.”
Known as precipitation, Zydney’s new protein purification process involves adding zinc chloride and polyethylene glycol, a water-soluble polymer, to a solution containing the antibody. This causes the antibody to precipitate so that the impurities can be washed away.
Though the precipitation process has been used for 70 years in blood plasma processing, it has never been used for the commercial production of antibodies, according to Zydney.
“To precipitate means ‘to come out’ of a solution in a solid form,” he said. “For example, when you put salt in warm water, it dissolves. But if you put a lot of salt into cold water, some of that salt will remain as solid crystals. In the same way, proteins would normally dissolve in a solution, but you can find certain conditions where they come out as solid.”
Zydney explained that the zinc chloride used in precipitation is a simple salt, making it much cheaper than other purification methods. It also saves time, as it is possible to yield large quantities of proteins in short periods of time.
Currently, antibodies are produced using a process called Protein A affinity chromatography, where the antibody binds to Protein A, which is immobilized in a chromatography column. The impurities can be washed away from the bound antibody, after which the pH level is adjusted to recover the purified antibody product. A single Protein A chromatography column can cost more than $10 million.
“That is just one step in the current manufacturing process, and it is what makes antibody manufacturing so expensive,” Zydney said. “All of the major biotechnology companies are big players in this space.”
The precipitation process eliminates the need for the costly chromatography process, as antibodies are purified directly from the solution by filtration through hollow fiber membranes.
“What we do in our research group is relatively small scale,” He said. “But the precipitation process has the potential to be easily scaled up, potentially enabling biopharmaceutical companies to produce lower-cost antibodies for the patients who need them.”
Todd Przybycien, professor of chemical and biological engineering at Rensselaer Polytechnic Institute, contributed to this research.
Original Article: Antibody injections could become more affordable with new production method
More from: Pennsylvania State University | Rensselaer Polytechnic Institute
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Antibody injections
- Royalty Pharma Drops $525M for Royalties and Milestones on Sanofi-Licensed MS Therapy
With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy frexalimab, which is currently in Phase III trials for multiple sclerosis.
- The Future of Antibody-Drug Conjugates in Lung Cancer Treatment
Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.
- Strengthening CAR-T therapy to work against solid tumors
Researchers have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors -- an advance that could transform cancer treatment. The promising findings involve ...
- Zenas raises $200m to advance autoimmune antibody therapy
Pacific territories for the bispecific antibody therapy, obexelimab, with Bristol Myers Squibb in September 2023.
- Global Antibody Therapy Market Poised for Remarkable Growth, Projected to Reach US$ 824 Billion by 2033 at a steady CAGR of 13.4%
The global antibody therapy market is set to witness robust expansion, with a projected Compound Annual Growth Rate (CAGR) of 13.4% from 2023 to 2033. According to recent market analysis, this growth ...
Go deeper with Google Headlines on:
Antibody injections
[google_news title=”” keyword=”antibody injections” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibody manufacturing
- MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call ...
- University of Houston project selected to join $10 million effort to innovate biopharmaceutical manufacturing
“In the course of the manufacturing processes, it's important to know the concentration of antibody in your sample and this measurement needs to be made many times in a typical manufacturing process,” ...
- Biosimilar Monoclonal Antibody Market Review: Annual Summary of Key Insights and Developments
Monoclonal antibodies are big protein molecules created to target ... concerning distribution and manufacturing. Simultaneously, COVID-19 stressed the significance of cost-effective biologic therapies ...
- Antibody Drug Conjugates Market Share Analysis: Top Players and Market Dynamics
The global antibody drug conjugates market size was US$ 4,990.8 million in 2021. The global antibody drug conjugates s market size is forecast to reach US$ 33,150.3 million by 2030, growing at a CAGR ...
- Fzata, Inc. Announces Successful FZ002 Manufacturing and Upcoming Phase 1 Clinical Trial
Fzata, Inc. is pleased to announce successful completion of a current good manufacturing practices (cGMP) run of lead drug, FZ002, with sufficient drug quantities to support the phase 1 first-in-human ...
Go deeper with Google Headlines on:
Antibody manufacturing
[google_news title=”” keyword=”antibody manufacturing” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]